Novo Nordisk (NVO) details insider vesting of 100th Anniversary restricted shares

Rhea-AI Filing Summary

Novo Nordisk A/S reports transactions in its B shares by members of the board of directors, executives and their associated persons, as required under Article 19 of the EU market abuse regulation. The reported transactions all relate to the vesting of shares under the Restricted Shares programme "Novo Nordisk 100th Anniversary Shares".

For each named board member and executive, including the President and CEO and several Executive Vice Presidents, 74 B shares (ISIN DK0062498333) vested at a reference price of DKK 294.30 per share, corresponding to an aggregated value of DKK 21,778.20 per individual transaction. All vestings occurred on 5 August 2026 outside a trading venue. Novo Nordisk notes its global healthcare focus on serious chronic diseases, with about 66,700 employees in 80 countries and products marketed in around 170 countries.

Key Figures

Shares vested per insider: 74 shares Reference share price: DKK 294.30 per share Value per vesting: DKK 21,778.20 +3 more

6 metrics

Shares vested per insider 74 shares Vesting under Novo Nordisk 100th Anniversary Restricted Shares programme for each named board member and executive

Reference share price DKK 294.30 per share Price used for the reported vesting transactions in Novo Nordisk B shares

Value per vesting DKK 21,778.20 Aggregated value of each individual’s 74-share vesting transaction

Employees 66,700 Number of people employed by Novo Nordisk worldwide

Countries with employees 80 countries Geographic spread of Novo Nordisk’s workforce

Countries where products are marketed around 170 countries Global market reach for Novo Nordisk’s products

Key Terms

market abuse, person discharging managerial responsibilities, Restricted Shares programme, American Depositary Receipts

4 terms

market abuse regulatory

"in accordance with Article 19 of Regulation No. 596/2014 on market abuse"

Market abuse is illegal or unethical behavior that distorts the price or fairness of buying and selling financial assets, such as using secret information to trade, spreading false or misleading news, or creating fake buying and selling to give a false impression of demand. It matters to investors because it can cause unfair losses, unreliable prices and legal or reputational fallout; like cheating in a game or tampering with a scale, it destroys confidence that markets reflect true value.

person discharging managerial responsibilities regulatory

"Details of the person discharging managerial responsibilities/person closely associated"

A person discharging managerial responsibilities is an individual who holds a senior role with authority to make or influence a company’s strategic or operational decisions, such as executives, board members, or other top managers. Investors care because these people often have access to confidential information and their buying or selling of company shares must be disclosed—like a referee who knows the score before the crowd, their actions can signal important, non-public insights about a company's prospects.

Restricted Shares programme financial

"vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares"

American Depositary Receipts financial

"Its ADRs are listed on the New York Stock Exchange (NVO)"

A certificate traded on U.S. markets that represents ownership of shares in a foreign company, letting U.S. investors buy and sell that company as if it were listed domestically. Think of it as a local voucher for a foreign product: it makes price quotes in dollars, trades on familiar exchanges, and brings differences in liquidity, fees and legal protections that can affect returns and risk compared with buying the underlying foreign shares directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/10/2026 - 10:42 AM Accepted by SEC EDGAR 08/10/2026 - 10:42 AM Learn about SEC filing dates

FAQ

What insider share transactions did Novo Nordisk (NVO) report in this 6-K?

Novo Nordisk reported vesting of restricted B shares for multiple board members and executives. Each individual received 74 shares under the Novo Nordisk 100th Anniversary Restricted Shares programme on 5 August 2026, outside a trading venue.

What was the value of the vested Novo Nordisk (NVO) shares per insider?

Each insider’s vesting corresponds to an aggregated value of DKK 21,778.20. This is based on 74 B shares vesting at a reference price of DKK 294.30 per share under the restricted share programme.

Which Novo Nordisk (NVO) executives had share vestings disclosed?

Disclosed recipients include the President and CEO and several Executive Vice Presidents, such as the CFO, heads of International Operations, Global Manufacturing & Supply, R&D, Enterprise IT & Quality, and People, Organisation & Corporate Affairs, each with 74 vested shares.

On what date did the Novo Nordisk (NVO) restricted shares vest?

All reported restricted B share transactions vested on 5 August 2026. The filing specifies this common transaction date for each board member and executive, and notes that the transactions took place outside a trading venue.

Under which programme did Novo Nordisk (NVO) insiders receive these shares?

The transactions arise from the vesting of shares under the Restricted Shares programme – Novo Nordisk 100th Anniversary Shares. This programme granted Novo Nordisk B shares that vested to board members and executives on 5 August 2026.

How large is Novo Nordisk’s (NVO) global workforce and footprint?

Novo Nordisk employs about 66,700 people in 80 countries and markets its products in around 170 countries. The company describes itself as a leading global healthcare company founded in 1923 and headquartered in Denmark.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

August 6, 2026

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 6 August 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	DÉSIRÈE JANTZEN ASGREEN
2	Reason for the notification
a)	Position/status	Member of the Board of Directors
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			DKK 294.30	74
		d)	Aggregated information · Aggregated volume ·  Price	74 shares DKK 21,778.20
e)	Date of the transaction	2026-08-05
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	ELISABETH DAHL CHRISTENSEN
2	Reason for the notification
a)	Position/status	Member of the Board of Directors
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			DKK 294.30	74
		d)	Aggregated information ·  Aggregated volume ·  Price	74 shares DKK 21,778.20
e)	Date of the transaction	2026-08-05
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	METTE BØJER JENSEN
2	Reason for the notification
a)	Position/status	Member of the Board of Directors
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			DKK 294.30	74
		d)	Aggregated information ·  Aggregated volume ·  Price	74 shares DKK 21,778.20
e)	Date of the transaction	2026-08-05
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	SEMSI KILIC MADSEN
2	Reason for the notification
a)	Position/status	Member of the Board of Directors
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			DKK 294.30	74
		d)	Aggregated information ·  Aggregated volume ·  Price	74 shares DKK 21,778.20
e)	Date of the transaction	2026-08-05
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	EMIL KONGSHØJ LARSEN
2	Reason for the notification
a)	Position/status	Executive Vice President, International Operations
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			DKK 294.30	74
		d)	Aggregated information ·  Aggregated volume ·  Price	74 shares DKK 21,778.20
e)	Date of the transaction	2026-08-05
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	KARSTEN MUNK KNUDSEN
2	Reason for the notification
a)	Position/status	Executive Vice President, Chief Financial Officer (CFO)
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			DKK 294.30	74
		d)	Aggregated information ·  Aggregated volume ·  Price	74 shares DKK 21,778.20
e)	Date of the transaction	2026-08-05
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	KASPER BØDKER MEJLVANG
2	Reason for the notification
a)	Position/status	Executive Vice President, Global Manufacturing & Supply
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			DKK 294.30	74
		d)	Aggregated information ·  Aggregated volume ·  Price	74 shares DKK 21,778.20
e)	Date of the transaction	2026-08-05
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	MAZIAR MIKE DOUSTDAR
2	Reason for the notification
a)	Position/status	President and CEO
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			DKK 294.30	74
		d)	Aggregated information ·  Aggregated volume ·  Price	74 shares DKK 21,778.20
e)	Date of the transaction	2026-08-05
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	MARTIN HOLST LANGE
2	Reason for the notification
a)	Position/status	Executive Vice President, R&D and Chief Scientific Officer (CSO)
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			DKK 294.30	74
		d)	Aggregated information ·  Aggregated volume ·  Price	74 shares DKK 21,778.20
e)	Date of the transaction	2026-08-05
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	THILDE GYNTHE BØGEBJERG KRØYER
2	Reason for the notification
a)	Position/status	Executive Vice President, Enterprise IT & Quality
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			DKK 294.30	74
		d)	Aggregated information ·  Aggregated volume ·  Price	74 shares DKK 21,778.20
e)	Date of the transaction	2026-08-05
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	TANIA SABROE
2	Reason for the notification
a)	Position/status	Executive Vice President, People, Organisation & Corporate Affairs
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			DKK 294.30	74
		d)	Aggregated information ·  Aggregated volume ·  Price	74 shares DKK 21,778.20
e)	Date of the transaction	2026-08-05
f)	Place of the transaction	Outside a trading venue

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com
Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com	Sina Meyer +45 3079 6656 azey@novonordisk.com
Alex Bruce +45 3444 2613 axeu@novonordisk.com	Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com
Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com	Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com
Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Alle 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 49 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: August 6, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer